IGI Logo

NPCI introduced a 0.4% MDR on P2M transactions above Rs2,000 from 15-Oct26, while leaving the mass market untouched — P2P transfers, sub-Rs2,000 tickets, and small P2PM merchants all remain free of charge, while select categories have lower MDR/capped per-transaction MDR. While 67% of the P2M transactions by value are above Rs2,000, we expect a lower eligible GMV. The more important signal, in our view, is that UPI acquiring now carries a commercial revenue model that is contractual, recurring, and scales with value, in place of a discretionary annual subsidy. This will make the payment business structurally self-sustaining, making the business model much more resilient. On conservative assumptions (ie 10bps/6bps realized take-rates for Paytm/Pine Labs), we estimate FY28 UPI MDR revenue of Rs11.2bn/Rs1.55bn, respectively. The present value of this stream adds Rs434bn and Rs51.2bn to our valuations for Paytm and Pine Labs, increasing our TP to Rs2,400 and Rs230, respectively. We maintain BUY on both Paytm and Pine Labs.

MDR on UPI - Issuing banks to keep the major part

Distribution of the 40bps MDR: issuing bank (16bps), acquiring bank (12bps), Payer TPAP (8bps), and Payer PSP bank (consumer handle, 4bps). While the issuing bank keeps the major part of the MDR, acquirers like Paytm and Pine Labs would keep the share of 12bps of the acquiring bank. MDR-eligible GMV: For Paytm, we assume UPI P2M constitutes 85% of GMV, of which 35% by value is MDR-eligible or Rs11.2trn in FY28E. The reason for keeping only 35% of the GMV eligible for MDR, despite 67% of the industry value being constituted for above-Rs2,000, is to factor in select categories that have caps on MDR. For Pine Labs, we estimate UPI P2M GTV of Rs3.0trn in FY28 (~12% of DITP GTV), of which 86% by value sits above the threshold, giving MDR-eligible GTV of Rs2.58trn (~10% of DITP GTV). Both ratios are held flat through the forecast period, with no migration of high-ticket payments to alternative rails assumed. Realized take-rate: We assume Paytm retains 10bps and Pine Labs 6bps of the pool 25% and 15%, respectively blended across the 0.4% headline slab, the flat Rs5 categories, and the 0.02% capital-market slab, yielding FY28E UPI MDR revenue of Rs11.2bn and Rs1.55bn. Valuation of the stream: We grow this revenue in line with our GMV CAGR of 21.5% over FY28-32E, taper it to 15% over FY33-42E, and assume 5% terminal growth, discounting at each company's WACC of 12.7% (Paytm) and 14.2% (Pine Labs). This yields incremental M-cap/EV accretion of Rs434bn and Rs51.2bn equivalent to Rs678/sh and Rs42/sh, with ~52% and 50% of the value residing in the terminal stage.

MDR on UPI - Key takeaways

The 0.4% MDR is capped at Rs300 for transactions of Rs75,000 and above. Specified sectors (railways, telecom, insurance, fuel, and agricultural inputs), accounting for ~46% of UPI P2M transaction value, will pay a flat Rs5 per transaction, for transaction value above Rs2,000. Capital market payments (MFs, securities, and stockbroking/dealer transactions) attract a lower 0.02% MDR, also capped at Rs300, while small merchants receiving up to Rs100k/month via UPI QR codes under the P2PM classification continue to enjoy 0 MDR. The framework applies only to direct account-to-merchant-account UPI transactions, excluding UPI-linked CC payments, and is expected to affect only ~4% of the overall merchant transaction volume.

Outlook and valuations

Adding the discounted value of this stream to our DCF-based valuations, Paytm's target Mcap increases to Rs1,536bn (target EV: Rs1,401bn), increasing our TP by 41.2% to Rs2,400 (from Rs1,700) and implying 38.2% upside. For Pine Labs, target M-cap increases to Rs278bn (target EV: Rs256bn) and our TP by 20.9% to Rs230 (from Rs190), implying 18.1% upside. At our revised TP, Paytm trades at 42.6x/30.1x FY28E/FY29E EV/EBITDA and 47.0x/32.8x PER, and Pine Labs at 23.9x/17.7x EV/EBITDA and 46.1x/32.7x PER. Optically rich on nearterm earnings, these multiples compress rapidly as operating leverage plays through — we estimate FY28-32E EBITDA CAGR of 32.6%/29.8% and PAT CAGR of 27.8%/36.4% for Paytm/Pine Labs — with the MDR stream accruing on rails and merchant relationships already in place. Key risks to our estimates are the eventual interchange-sharing formula (which the circular leaves open), value leaking to merchants through competitive discounting as acquirers grapple for large-ticket flow, and elasticity at the Rs2,000 threshold (which we have not modelled in).

For More  Emkay Global Financial Services Ltd Disclaimer http://www.emkayglobal.com/Uploads/disclaimer.pdf & SEBI Registration number is INH000000354